Key Investor Signals
Retrospective validation in 127 patients
A retrospective study of 127 patients, posted on medRxiv, reported an area under the curve of 0.731 for vasospasm or delayed cerebral ischaemia and 0.857 for death.
Granted patents in the United States and Europe
The underlying method is covered by granted United States and European patents held by the Servicio Andaluz de Salud, the Andalusian public health service.
Available for research use on the QMENTA platform
HOP is publicly available for research use through QMENTA, a cloud platform used by clinical researchers to store and analyse medical imaging data.
Other Positive Signals
- Selected as the first spin-off supported by ITEMAS, Spain's public network for medical technology innovation, under its HOP2Market project.
- Won a €30,000 Basque public innovation award supporting early commercialization.
Team
Marcin Balcerzyk
Founder
- Holds a PhD in physics and has worked for more than two decades in medical imaging research across Spain, France and Poland.
- Led imaging research at CNA, the national accelerator centre in Seville, covering PET, CT and quantitative image analysis.
- Named inventor on the granted United States and European patents covering the outcome-prediction method behind HOP.
Product
HOP combines routine CT imaging with clinical data recorded at admission and returns three outcome estimates for patients after subarachnoid haemorrhage. It is currently offered for Research Use Only through the QMENTA platform.
Built on routine CT scans
The method uses the CT scan already acquired when a patient is admitted, together with recorded clinical variables, so it requires no additional imaging or hardware.
Three outcome estimates
HOP produces estimates for cerebral vasospasm or delayed cerebral ischaemia, functional outcome and death, giving neurocritical teams an early view of risk.
Delivered through an established research platform
HOP runs on QMENTA, a cloud platform for medical imaging research, which handles data storage and processing without new hospital IT deployment.
Market Overview
Aneurysmal subarachnoid haemorrhage is a sudden bleed around the brain that affects roughly half a million people worldwide each year. Survivors face a high risk of secondary complications in the following days, especially cerebral vasospasm and delayed cerebral ischaemia, which can cause lasting disability or death.
Care takes place in neurocritical units where clinicians must decide how intensively to monitor each patient. Those decisions currently rest on clinical scales and specialist judgement, and intensive care days are expensive, so tools that stratify risk early have direct clinical and economic relevance.
Estimated global incidence of aneurysmal subarachnoid haemorrhage each year.
Reported mean cost of a subarachnoid haemorrhage hospital admission in published analyses.
Size of the clinical cohort referenced in the underlying research on outcome prediction.
Estimated market value for AI-supported medical imaging in neurology applications.
Comparable Outcomes
Hyperfine
Hyperfine developed a portable MRI system designed to bring brain imaging to the bedside, including in intensive care settings. The company went public through a business combination valuing it at approximately $580M in enterprise value.
Butterfly Network
Butterfly Network built a handheld, semiconductor-based ultrasound device paired with software for point-of-care imaging. It listed publicly at approximately $1.5B in enterprise value.
Interested in More Startups Like CT Provision?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.